Hydrazine

Hydrazine

SCHEMBL7038883

CC(C)=CCC(c1ccc(OCc2ccccc2)cc1)C(C)C.NN

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.49
MAOB P27338 1/20 0.49
LTA4H P09960 1/20 0.47
PARP10 Q53GL7 1/20 0.46
ACACB O00763 1/20 0.46
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
PTGS1 P23219 1/20 0.45
SLC6A2 P23975 1/20 0.45
CYP2C19 P33261 1/20 0.45
PTGS2 P35354 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HIF1A Q16665 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
NR4A1 P22736 1/20 0.44
NR4A2 P43354 1/20 0.44
NR4A3 Q92570 1/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12120651 0.74 ALOX5 (0.48) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL7353502 0.74 LTA4H (0.50) ALOX5MAOBLTA4HACACBNPC1
Hydrazine SCHEMBL7361825 0.73 LTA4H (0.48) ALOX5MAOBLTA4H
SCHEMBL10077075 0.73 MAOB (0.50) ALOX5MAOBACACBLMNACYP1A2
SCHEMBL6616547 0.73 LMNA (0.56) ALOX5MAOBLTA4HLMNACYP1A2
SCHEMBL6376299 0.73 MAOB (0.59) ALOX5MAOBLTA4HLMNACYP1A2
SCHEMBL1497960 0.73 LMNA (0.61) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL7768214 0.73 MAOB (0.59) ALOX5MAOBLTA4HLMNACYP1A2
SCHEMBL7043509 0.72 NPC1 (0.48) ALOX5MAOBLTA4HACACBLMNA
SCHEMBL28045714 0.72 MAOB (0.60) ALOX5MAOBPARP10ACACBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060632-A1 Calcium channel blockers HU LAIN-YEN (US) 2003-03-27 US disclosed
US-6495715-B2 STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS WARNER-LAMBERT COMPANY 2002-12-17 US disclosed
US-20010023249-A1 Calcium channel blockers HU LAIN-YEN (US) 2001-09-20 US disclosed
US-6251918-B1 FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY WARNER-LAMBERT COMPANY 2001-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023249-A1 Calcium channel blockers CACNA1I, CACNA1B, CACNA1G ALOX5 723/4885MAOB 613/4885LTA4H 759/4885
US-20030060632-A1 Calcium channel blockers CACNA1I, CACNA1B, CACNA1G ALOX5 723/4885MAOB 613/4885LTA4H 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.